iNVEZZ.com, Friday, June 27: GlaxoSmithKline Plc’s (LON:GSK) ViiV Healthcare joint venture has received a positive opinion by a committee of the European Medicine Agency (EMA) for its investigational single-tablet HIV treatment which combines three separate drugs.
GSK’s share price has added just under 0.6 percent in London so far today.
**Triumeq receives EMA approval**
GSK announced today in a statement that the EMA’s Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for ViiV Healthcare’s first investigational once-daily single-tablet HIV treatment Triumeq which combines integrase inhibitor dolutegravir and nucleoside analogues abacavir/lamivudine.
“Today’s positive opinion takes us a step closer to bringing physicians and people living with HIV a dolutegravir based regimen that can be taken once-daily as a single-tablet,” John Pottage, ViiV’s chief scientific and medical officer said in the statement. “This opinion supports the potential of dolutegravir based regimens, as well as the importance of our ongoing research into additional single-tablet treatment options.”
A positive opinion from the EMA’s CHMP is generally followed by marketing authorisation from the European Commission, with GSK anticipating a final decision in the third quarter. ViiV’s Triumeq is also currently under review by the US Food and Drug Administration.
Earlier this year, the Commission approved ViiV’s dolutegravir under the brand name Tivicay for use in combination with other anti-retroviral medicines for the treatment of HIV-infected adults and adolescents above 12 years of age. (GSK share price: ViiV Healthcare’s Tivicay gets European approval – https://invezz.com/news/equities/8241-gsk-share-price-viiv-healthcares-tivicay-gets-european-approval) GSK is the biggest shareholder in ViiV Healthcare, with Pfizer Inc (NYSE:PFE) and Japan’s Shionogi & Co Ltd (TYO:4507) holding minority stakes.
Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.
Earlier this month, ViiV teamed up with Johnson & Johnson’s (NYSE:JNJ) Janssen R&D unit to develop a new HIV treatment combining Tivicay and Janssen’s Eduran, or rilpivirine, in a single tablet. (GSK share price: ViiV Healthcare teams up with J&J unit – https://invezz.com/news/equities/11487-gsk-share-price-viiv-healthcare-teams-up-with-j-and-j-unit)
**Analysts on GSK**
The 24 analysts offering 12-month price targets for GSK for the Financial Times have a median target of 1,690p, with a high estimate of 3,546.2p and a low estimate of 1,500p. As of June 26, the consensus forecast amongst 50 polled investment analysts covering the stock advises investors to hold their position in the FTSE 100 drug maker.
**As of 14:19 BST, buy GSK shares at 1573.00p.**
**As of 14:19 BST, sell GSK shares at 1572.00p.**